The answer to that question may well depend on "why" it had a negligible effect - if indeed it did. Much has been made of the similarities between the HCV and HBV treatments. If, for example, the vector was a problem, then it would make sense for the TT-034 results to be delayed in order to buy time to develop a new vector. Then, when the TT-034 data is released, the company will be able to point to a change in the design of the HBV treatment which eliminates the problem.
If big pharma is actually sniffing around, I am sure that they would want to be assured that any shortcomings of TT-034 will be overcome for HBV before signing any deal.
TT-034 data collection finishes this month, so we don't have long to wait.
Panno speaks on recent changes, page-4
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)